title: [Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial].
abstract: OBJECTIVE
  To ed evaluate the clinical effects of autologous cytokine-induced killer cell (CIK) fusion to lower recurrence of primary hepatocellular carcinoma (HCC) and the anti-hepatitis B virus (HBV) effect after transcatheter arterial chemoembolization (TACE) sequentially combined with radiofrequency ablation (RFA).
  
  
  METHODS
  Sixty-four HCC patients underwent TACE sequentially combined with RFA without residual tumor or extrahepatic metastasis were randomly divided into 2 groups: study group (n = 33), receiving autologous CIK fusion of the dose of (1.1 - 1.5) x 10(10) via the peripheral vein or hepatic artery, firstly once every 3 - 4 weeks for 4 times, and then once every 4 weeks for 4 times; and control group (n = 31). All patients were followed up for 1 year.
  
  
  RESULTS
  In the study group, 29 patients (29/33) were recurrence-free during the 1 year follow-up, 3 had recurrence in the liver 5, 6, and 7 months later respectively, and 1 patient had lymphoadenopathy in the hepatic portal 9 months later. In the control group, 23 patients (68.01%) were recurrence-free, 7 had recurrence in the liver within 1 year, and 1 had lung metastasis 11 months later. In the study group, the number of the patients with the HBV DNA content < 1 x 10(3) before treatment was 19, and increased to 29 after the treatment; 2 of the 19 patients who were HBsAg positive before the treatment became HBsAg negative after the treatment, and number of the patients with the HBV DNA content of 10(3) - 10(4) was 3 before the treatment, and became 13 after the treatment among which 1 patient had his HBV DNA content dropping from 1.6 x 10(7) to 1.6 x 10(4). In the control group, only 1 patient showed his HBV DNA content dropping from 1.1 x 10(5) to below 10(3).
  
  
  CONCLUSIONS
  Capable of reducing recurrence, prolonging the recurrence-free span, and attacking HBV, autologous CIK fusion after TACE sequentially combined with RFA is an effective novel therapeutic strategy for HCC.
authors.affiliation: Department of Imaging and Interventional Radiology, Cancer Hospital, Sun Yat-sen University, State key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.forename: Pei-hong
authors.initials: PH
authors.lastname: Wu
authors.forename: Yi-xin
authors.initials: YX
authors.lastname: Zeng
authors.forename: Jian-chuan
authors.initials: JC
authors.lastname: Xia
authors.forename: Fu-jun
authors.initials: FJ
authors.lastname: Zhang
authors.forename: Li-jian
authors.initials: LJ
authors.lastname: Xian
authors.forename: Yu-ping
authors.initials: YP
authors.lastname: Zhang
authors.forename: Kun
authors.initials: K
authors.lastname: Zhou
authors.forename: Wei-jun
authors.initials: WJ
authors.lastname: Fan
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.forename: Qi-ming
authors.initials: QM
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D017619:Hemibody Irradiation / Q000379:methods; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007694:Killer Cells, Natural / Q000637:transplantation; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D004279:DNA, Viral